Atrium Therapeutics, Inc. Common Stock (RNA)

• Market cap: $231M
• 1 day: 0.88%
• 5 days: -2.61%
• 1 month: 1.15%
• 3 months: 1.15%
• 6 months: 1.15%
• Year to date: 1.15%
• 1 year: 1.15%
• 5 years: 1.15%
• 10 years: 1.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Employees: 391